OPTHEA LIMITED (OPT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

OPT - OPTHEA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index: ALL-ORDS

Opthea is an Australian healthcare company specialising in the development and commercialisation of therapies to combat eye diseases. Founded in 1984, the company listed on the ASX in 1991.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.405

25 Jul
2024

0.000

OPEN

$0.41

0.000

HIGH

$0.43

2,714,213

LOW

$0.39

TARGET
$0.70 72.8% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
OPT: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 41.6 - 24.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-41.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.2 M
Book Value Per Share xxxxxxxxxxxxxxx-1.6
Net Operating Cash Flow xxxxxxxxxxxxxxx-179.3 M
Net Profit Margin xxxxxxxxxxxxxxx-131,469.74 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-694.96 %
Return on Invested Capital xxxxxxxxxxxxxxx-693.52 %
Return on Assets xxxxxxxxxxxxxxx-179.93 %
Return on Equity xxxxxxxxxxxxxxx-694.96 %
Return on Total Capital xxxxxxxxxxxxxxx-729.64 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-179.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx134 M
Price To Book Value xxxxxxxxxxxxxxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx20.25 %
Cost of Goods Sold xxxxxxxxxxxxxxx-
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx223 M
Research & Development xxxxxxxxxxxxxxx182 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

25/07/2024

1

Initiation of coverage with Buy

$0.70

72.84%

Bell Potter reinitiates coverage on Opthea after a four-year absence with a Speculative Buy rating and 70c target price.

The company is developing a new drug sozinibercept to treat common retinal diseases, particularly wet-age-related macular degeneration, which is the leading cause of vision loss in older people and to date has represented a $5bn market.

Bell Potter says the Opthea's solution stands out from an otherwise undifferentiated market by targeting a new pathway in the retina, which it expects will provide superior outcomes - the first drug to do so in 15 years, says Bell Potter.

The drug is in the clinical phase as the company progresses two large (the biggest readouts for an ASX-listed biotech in recent history) Phase III trials, fully recruited with readouts scheduled for early and mid 2025.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -24.30 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -20.60 cents.
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >

OPT STOCK CHART

FNArena News on OPT

1
Rudi’s View: February 2024 Is A Blue Sky Affair

Feb 14 2024 - Rudi's View
2
Australian Broker Call *Extra* Edition – Oct 18, 2023

Oct 18 2023 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Aug 30, 2023

Aug 30 2023 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Jul 27, 2023

Jul 27 2023 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Sep 13, 2022

Sep 13 2022 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Shares Breaking Free

Jul 23 2024 - Technicals
2
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
3
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
4
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
5
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
6
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
7
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps
8
Is The Long Wait For CSL About To End?

May 30 2024 - Technicals
9
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
10
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps